EUVIMEDEUVIMED entdecken
Open Access

Adverse Effects of Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: Real‐World Single Institution Experience

Avivah J Wang iD, Rong Jiang, Tami Runyan, Ralph Abi Hachem, Bradley J Goldstein iD, David W Jang iD

The Laryngoscope · 2025

DOI: 10.1002/lary.32359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Laryngoscope, 2025. Verfasst von Avivah J Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Sinusitis, Antibodies, Monoclonal, Humanized, Rhinitis, Nasal Polyps. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCD NIH HHS, National Institute on Deafness and Other Communication Disorders.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Phase III trials have shown that dupilumab is an effective and well‐tolerated adjunct treatment for patients with uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). However, real‐world data pertaining to tolerability and adverse effects (AE) are lacking. The goal of this study is to investigate AE incidence, timing, and medication discontinuation.

Methods

This is a retrospective cohort study at a single tertiary care institution. Patients initiating treatment with dupilumab for CRSwNP over a four‐year period (2020–2023) with at least six months of follow‐up were included. Univariate analysis and multivariable logistic regression were performed to investigate relevant clinical factors associated with AEs. Univariate analysis was also performed to determine factors associated with discontinuation due to AEs.

Results

115 patients received at least one dose of dupilumab. Mean age (SD) was 51.0 (14.9) years, and 44% were female. 39 patients reported at least one AE, with 15 having more than one AE. 15 patients (13.0%) discontinued the medication due to an AE. Ocular AEs were the most common (15), followed by injection site reactions (10), musculoskeletal (9), and non‐injection site skin reactions (8). Female sex was significantly associated with AEs and discontinuation due to AEs.

Conclusion

While dupilumab is an effective treatment option for uncontrolled CRSwNP, the incidence of AEs and discontinuation rates were higher than reported in Phase III trials. Additional real‐world data pertaining to AEs can aid in clinical decision‐making and patient counseling. Level of Evidence 4

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SinusitisAntibodies, Monoclonal, HumanizedRhinitisNasal PolypsHumansFemaleMaleRetrospective StudiesMiddle AgedChronic DiseaseAdultAgedRhinosinusitis

Stichwörter der Autor:innen

biologicsdupilumabnasal polypssinus diseasesinusitis

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Duke University School of Medicine, Durham, North Carolina, USA.
  • Department of Head and Neck Surgery and Communication Sciences, Duke University School of Medicine, Durham, North Carolina, USA.

ORCID-Profile: Avivah J Wang, Bradley J Goldstein, David W Jang

Förderung

  • NIDCD NIH HHS
  • National Institute on Deafness and Other Communication Disorders

Zitieren

APA

Wang, A. J., Jiang, R., Runyan, T., Abi Hachem, R., Goldstein, B. J., & Jang, D. W. (2025). Adverse Effects of Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: Real‐World Single Institution Experience. The Laryngoscope. https://doi.org/10.1002/lary.32359

Vancouver

Wang AJ, Jiang R, Runyan T, Abi Hachem R, Goldstein BJ, Jang DW. Adverse Effects of Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: Real‐World Single Institution Experience. The Laryngoscope. 2025. doi:10.1002/lary.32359

BibTeX
@article{Wang2025,
  author = {Wang, Avivah J and Jiang, Rong and Runyan, Tami and Abi Hachem, Ralph and Goldstein, Bradley J and Jang, David W},
  title = {Adverse Effects of Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: Real‐World Single Institution Experience},
  journal = {The Laryngoscope},
  year = {2025},
  doi = {10.1002/lary.32359}
}
Kostenlos starten →